Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.55 |
| ▸ | DDB1 | Q16531 | 16/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26641534 | 0.92 | CRBN (0.49) | CRBNDDB1POLB | |
| SCHEMBL30694226 | 0.89 | CRBN (0.51) | CRBNDDB1POLBGSPT1NAMPT | |
| SCHEMBL25188462 | 0.86 | HSD17B10 (0.48) | CRBNDDB1POLB | |
| SCHEMBL31382245 | 0.85 | CRBN (0.55) | CRBNDDB1POLB | |
| SCHEMBL31382100 | 0.85 | CRBN (0.55) | CRBNDDB1POLB | |
| SCHEMBL25195064 | 0.85 | CRBN (0.55) | CRBNDDB1POLB | |
| SCHEMBL31382246 | 0.85 | CRBN (0.55) | CRBNDDB1POLB | |
| SCHEMBL25074059 | 0.84 | ALDH1A1 (0.50) | CRBNDDB1POLBNAMPT | |
| SCHEMBL25187951 | 0.84 | CRBN (0.57) | CRBNDDB1POLBGSPT1 | |
| SCHEMBL30955758 | 0.84 | CRBN (0.51) | CRBNDDB1POLBGSPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024141052-A1 | ESTROGEN-RECEPTOR MODULATOR AND USE THEREOF | 江苏威凯尔医药科技有限公司 | 2024-07-04 | — | — | WO | disclosed |
| WO-2024102849-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING 2,5-SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2023249970-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023250029-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023249968-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-DJPYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | CRBN 2136/4885DDB1 132/4885POLB 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.